Ceftriaxone treatment

Phase 2Small molecule

NNantes University Hospital

Ceftriaxone treatment is one of 4 small molecule programs targeting Lyme disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lyme DiseaseRecruiting

Lyme DiseasePhase 2

Recruiting

Competition

Competitive Landscape

3 competitors in Lyme Disease

#DrugCompanyPhaseTrials

Achromycin V

WWyeth-Lederle Vaccines

VLA15

3 3

Mrna-1982

Moderna

Phase 2

2 4

Ceftriaxone treatment

NNantes University Hospital

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1/2Recruiting

Lyme Disease

NCT06785402

Clinical

Trials by Indication[1]

Lyme disease1 trial

Ceftriaxone for Post-Treatment Lyme Disease

Recruiting·HHackensack Meridian Health·Phase 1/2·NCT06785402·20 enrolled

Unspecified1 trial

Pharmacological Study of High Doses of Ceftriaxone in Meningitidis

Completed·NNantes University Hospital·Phase 4·NCT01745679·198 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Ceftriaxone treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ceftriaxone treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ceftriaxone treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nantes University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNantes University Hospital

Ceftriaxone treatment

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Lyme disease1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News